TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00836784

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: old toothbrush
Description: All children will receive new tooth brush 3 months before starting the study, at the end of 3 month the worn tooth brushes will be returned and the surface area within the outline will be determine using NIH (national institutes of health) image software.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New tooth brush
Description: The tooth brush which will be use in this study is Jordan. A new Jordan toothbrush will be give to all children, and in new tooth brush group they will use these toothbrushes.
Study: NCT00580892

Intervention type: DEVICE
Intervention: Optical Coherence Tomography imaging
Description: Optical Coherence Tomography imaging
Study: NCT02939768

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ST combined with HIIT (ST+HIIT)
Description: Participants in the ST+HIIT group will execute ST and HIIT (in this order) above described in the same training session, lasting approximately 60 min. This intervention will last 10 weeks.
Study: NCT02447809

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: (ASA 100mg daily and Clopidogre 75mg daily)\* 12 month.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: (ASA 100mg daily and Clopidogre 75mg daily)\* 12 month.
Study: NCT04152863

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gebasaxturev IV
Description: Administered as an IV infusion of 1 X 10\^9 TCID50

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gebasaxturev ITu
Description: Administered as an ITu injection of 3 X 10\^8 TCID50

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered as an IV infusion of 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered as an IV infusion of 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered as an IV infusion of 200 mg
Study: NCT02447809

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetylsalicylic acid (ASA)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid (ASA)
Study: NCT03534154

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Magnetic Resonance Imaging

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Magnetic Resonance Imaging

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Magnetic Resonance Imaging
Study: NCT03271684

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-management
Description: one session of up to one-hour per week over a six-week period in addition to their usual rehabilitation. During each session strategies will be used to promote specific behaviors that exemplify the hallmarks of self-management. These behaviors include enabling patients to work out ways of taking control of their daily lives by setting small targets, recording their progress and problem-solving. The content of the sessions is determined by the patient and their personal goals rather than being professionally directed

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Participants will receive usual rehabilitation treatment, they will also be given a booklet with education program and exercises they can perform at home.
Study: NCT04391296

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arm I (Prepectoral), Arm II (Subpectoral)
Description: Arm I (Prepectoral)De-epithelialized skin flaps are made from the inferior pole of breast skin and soft tissue. The implant pocket is shaped by fixing a sufficiently large amount of ADM to the medial surface of the mastectomy pocket, the upper edge of the pectoralis major muscle and the de-epithelial skin flap. The implant is located in the prepectoral mastectomy pocket and the ADM anchored to the chest wall, serratus fascia, and de-epithelial skin flaps. The pectoralis major muscle is located in the anatomical location behind the ADM.~Arm II (Subpectoral)The pectoralis major muscle is dissected from the thorax to create sufficient space for the implant to be placed behind the pectoralis major muscle. Implant pockets are made by suturing the lower part of the elevated pectoralis major muscle to the top of the de-epithelial skin flap and the ADM patch to the skin flap, the pectoralis major muscle, and the lateral thoracic fascia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arm I (Prepectoral), Arm II (Subpectoral)
Description: Arm I (Prepectoral)De-epithelialized skin flaps are made from the inferior pole of breast skin and soft tissue. The implant pocket is shaped by fixing a sufficiently large amount of ADM to the medial surface of the mastectomy pocket, the upper edge of the pectoralis major muscle and the de-epithelial skin flap. The implant is located in the prepectoral mastectomy pocket and the ADM anchored to the chest wall, serratus fascia, and de-epithelial skin flaps. The pectoralis major muscle is located in the anatomical location behind the ADM.~Arm II (Subpectoral)The pectoralis major muscle is dissected from the thorax to create sufficient space for the implant to be placed behind the pectoralis major muscle. Implant pockets are made by suturing the lower part of the elevated pectoralis major muscle to the top of the de-epithelial skin flap and the ADM patch to the skin flap, the pectoralis major muscle, and the lateral thoracic fascia.
Study: NCT01639157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone
Description: Subjects will be maintained on oral buspirone (10 mg administered 3 times daily) for 6 days each during the study in random order.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be maintained on oral placebo (0 mg administered 3 times daily) for 6 days each during the study in random order.
Study: NCT03534154

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Magnetic Resonance Imaging

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Sampling
Description: Sampling of serum

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Sampling
Description: Sampling of serum
Study: NCT03335514

Intervention type: DIAGNOSTIC_TEST
Intervention: expression of GALNT4
Description: Blood is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture and the total RNA was extracted from blood.Realtime PCR was performed to measure the expression of GALNT4.

Intervention type: DIAGNOSTIC_TEST
Intervention: expression of GALNT4
Description: Blood is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture and the total RNA was extracted from blood.Realtime PCR was performed to measure the expression of GALNT4.

Intervention type: DIAGNOSTIC_TEST
Intervention: expression of GALNT4
Description: Blood is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture and the total RNA was extracted from blood.Realtime PCR was performed to measure the expression of GALNT4.

Intervention type: DIAGNOSTIC_TEST
Intervention: expression of GALNT4
Description: Blood is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture and the total RNA was extracted from blood.Realtime PCR was performed to measure the expression of GALNT4.
Study: NCT03534154

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Sampling
Description: Sampling of serum

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Sampling
Description: Sampling of serum

Intervention type: DIAGNOSTIC_TEST
Intervention: Microdialysis
Description: Monitoring of cerebral fluid protein levels

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological tests
Description: Battery of tests to assess cognitive function, patient outcomes

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological tests
Description: Battery of tests to assess cognitive function, patient outcomes

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological tests
Description: Battery of tests to assess cognitive function, patient outcomes

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological tests
Description: Battery of tests to assess cognitive function, patient outcomes

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI (advanced)
Description: Advanced MRI

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI (advanced)
Description: Advanced MRI
Study: NCT05162209

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Synbiotic
Description: Oral sachet, for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synbiotic
Description: Oral sachet, for 12 weeks
Study: NCT02065232

Intervention type: DRUG
Intervention: Tilmanocept
Study: NCT01461538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 1.8 mg/kg every 3 weeks by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 2.4 mg/kg every 3 weeks by intravenous (IV) infusion
Study: NCT02065232

Intervention type: DRUG
Intervention: Sulfur Colloid
Study: NCT04177602

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil chemoradiation
Description: Trifluridine/tipiracil based chemoradiation

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine based chemoradiation
Description: Capecitabine based chemoradiation
Study: NCT00471848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabbit antithymocyte globulin
Description: 1.5 vials/10kg daily for 5 days
Study: NCT03515772

Intervention type: DRUG
Intervention: Co-administration of darunavir with a cardiovascular drug
Description: Co-administration of darunavir, an HIV agent considered prone to induce drug interactions, with a cardiovascular drug (amlodipine, atorvastatin or rosuvastatin). Note that a patient will be able to participate in the intervention group and the control group if a change in his/her anti-HIV treatment occurs (study partly parallel and partly in cross-over).

Intervention type: DRUG
Intervention: Co-administration of darunavir with a cardiovascular drug
Description: Co-administration of darunavir, an HIV agent considered prone to induce drug interactions, with a cardiovascular drug (amlodipine, atorvastatin or rosuvastatin). Note that a patient will be able to participate in the intervention group and the control group if a change in his/her anti-HIV treatment occurs (study partly parallel and partly in cross-over).

Intervention type: DRUG
Intervention: Co-administration of darunavir with a cardiovascular drug
Description: Co-administration of darunavir, an HIV agent considered prone to induce drug interactions, with a cardiovascular drug (amlodipine, atorvastatin or rosuvastatin). Note that a patient will be able to participate in the intervention group and the control group if a change in his/her anti-HIV treatment occurs (study partly parallel and partly in cross-over).
Study: NCT00736008

Intervention type: OTHER
Intervention: Observational
Description: Data summary only
Study: NCT00708344

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irbesartan - Hydrochlorothiazide
Description: 150/12.5 mg (1 tablet once daily) or 300/25 mg (1 tablet once daily) depending on the control of the blood pressure. Treatment duration : 10 weeks
Study: NCT00074399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: Tablet taken orally daily. Dosage depends on age and body surface area

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nevirapine placebo
Description: Placebo tablet taken orally daily
Study: NCT00945945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine (DLX)
Description: dose daily by mouth

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Duloxetine (DLX)
Description: dose daily by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (PLA)
Description: Placebo Comparator daily by mouth

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (PLA)
Description: Placebo Comparator daily by mouth
Study: NCT03655951

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based resource on adolescent sexual health
Description: Web-based resource on adolescent sexual health than the intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alternate web-based resource on adolescent sexual health
Description: This is a different web-based resource on adolescent sexual health than the intervention.
Study: NCT01549327

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oncology Interactive Navigator

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Care
Study: NCT01556581

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care (UC)
Description: Initial management for all patients will include an activity-limiting profile for up to 30 days and a 10-day supply of medications if needed (NSAIDs and muscle relaxers). All patients will then receive advice and education about the favorable natural history of LBP and the advantages of remaining as active as possible. All patients will be recommended to follow-up with their primary care provider using normal procedures if they are not satisfied with their progress.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early Physical Therapy (PT)
Description: Patients in the early PT group will receive the same treatment as the usual care group, but will then be referred to physical therapy within 3 days. The physical therapy treatment will be based on the Treatment Based Classification system (an approach that places patients into either an extension-oriented, core strength/stabilization, or a spinal manipulation treatment group based on signs and symptoms).
Study: NCT02081144

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smokefree TXT Program
Description: The SmokeFreeTxt program is a library consisting of \~130 brief messages that can be proactively sent to smokers' cellphones using software developed and maintained by NCI. The message content is informed by principles of cognitive behavioral therapy. They are sent to smokers at random times of day (during normal waking hours), up to 5 messages per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine replacement patches
Description: Subject will be given 4 weeks of Nicotine Replacement Patches, based on the amount he/she is smoking at baseline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Gum
Description: Subjects will be given 10 pieces of 2mg Nicotine Replacement Gum x 28 days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Faxed Referral CT Smokers Quitline
Description: A faxed referral will be sent to the CT Smokers Quitline for the subject.
Study: NCT03647228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IONIS-ENaCRx
Description: Ascending single and multiple doses of IONIS-ENaCRx inhaled or nebulized.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator calculated volume to match active comparator inhaled or nebulized.
Study: NCT01296256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine-EAM
Description: Bendamustine 200 mg/m2 starting dose on day -7 and -6 Etoposide 200 mg/m2 from day -5 to day -2 Ara-C 400 mg/m2 from day -5 to day -2 Melphalan 140 mg/m2 on day -1
Study: NCT02291055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADXS11-001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADXS11-001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADXS11-001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADXS11-001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Study: NCT04035161

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Investigational Product
Description: 2%(w/v) Chlorhexidine in 70%(v/v) Isopropyl skin preparation

Intervention type: OTHER
Group type: OTHER
Intervention: Reference Standard
Description: 60% (v/v) 1-propanol skin preparation

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: ChloraPrep® SEPP® skin preparation

Intervention type: OTHER
Group type: OTHER
Intervention: Negative Control
Description: 0.9% Normal Saline skin preparation
Study: NCT01089439

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitric oxide by inhalation INOMAX
Description: Nitric oxide by inhalation INOMAX 800 ppm~40 ppm during 24 hours then 20 ppm during 24 hours then 10 ppm during 24 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT02227342

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant
Description: serial FMT
Study: NCT03809520

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: pedCAT
Description: Weight-bearing CT scan (pedCAT) of ankles to measure 3D joint space width following ankle fracture.
Study: NCT04246606

Intervention type: DIAGNOSTIC_TEST
Intervention: IHC4 score
Description: The IHC4 score is a prognostic tool that incorporates immunohistochemical parameters of ER (H-score), PR (% of positive cells), HER2 (positive or negative status), and Ki67 (% of positive cells).~IHC4 score, combined with nodal status and tumor grade, age, and the type of endocrine therapy (tamoxifen or aromatase inhibitors) provides a clinical score IHC4+C.~IHC4+C provides a prognostic risk of distant recurrence at 10 years for patients who underwent endocrine therapy for 5 years. IHC4+C defined three distinct risk categories:~* \<10%: low risk~* \[10-20%\]: intermediate risk~* \>20%: high risk
Study: NCT01004588

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein drink
Description: total of 15 g protein/d in a protein drink consumed every morning after breakfast during 24 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo drink
Description: subjects consume a placebo drink every morning after breakfast over a period of 24 weeks.
Study: NCT00559520

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Impact
Description: Patient receiving 3 drinks Impact a day during 5 days before surgery

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Impact
Description: Patient receiving 3 drinks Oral Impact a day during 5 days before surgery
Study: NCT02722447

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rivaroxaban
Description: Rivaroxaban 20 mg for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for 6 weeks
Study: NCT00977132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic aicd
Description: Treatment with VPA starts at day1, the dose ist slowly increase according to the following scheme~day morning dose midday dose evening dose contents of 1 tablet~1+2 0 0 1 500 mg~3+4 ½ 0 1 500 mg~5+6 1 0 1 500 mg~7+8 1 ½ 1 500 mg~9+10 1 1 1 500 mg~11+12 1 1 1 500 mg~In the morning of day 13 trough level of VPA will be checked. The target range will be 50-110 µg/l. The dose of VPA will be adjusted depending on the trough level. In the first eight weeks of therapy weekly controls of VPA levels are required. Thereafter, VPA levels will be checked every four weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 5 mg/day, continuous therapy~Dosing will be in the morning at approximately the same time each day. Capsules may be taken before or after a meal.~Only one cycle of study drug (28 days) will be supplied to the patient every four weeks
Study: NCT03233958

Intervention type: BEHAVIORAL
Intervention: Systemic / family constellation
Description: Systemic / family constellation integrates elements from psychodrama, family sculpture, and spontaneous dramatizations of intra- and interpersonal processes, while spatially visualizing family dynamics. Family constellations stimulate change through the following ways: 1) making visible the spatial arrangement of relationships within a conflictual system; 2) providing access to the insights of unrelated third parties regarding the sensations, feelings, and thoughts they experienced while representing family members within the constellation; and 3) making observable (from the outside) and experienceable (from within) the transformation of the problem constellation into the solution constellation \[Hunger, Weinhold, Bornhäuser, Link, \& Schweitzer, 2015\].
Study: NCT02487212

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.05% Clobetasol propionate
Description: 0.05% Clobetasol propionate was rubbed for 2 minutes on one side of the scar immediately after treated with fractional Erbium: YAG (2,940-nm) laser. The treatment was done in every 2 weeks for 4 sessions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Petrolatum gel
Description: Petrolatum gel was rubbed for 2 minutes on the other side of the scar immediately after treated with fractional Erbium: YAG (2,940-nm) laser.The treatment was done in every 2 weeks for 4 sessions

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Fractional Erbium:Yag (2,940-nm) laser
Description: The parameter of the laser was 28 J/cm2, 5% spot density, 1 pass for the whole scar. The treatment was done in every 2 weeks for 4 sessions

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional Erbium:Yag (2,940-nm) laser
Description: The parameter of the laser was 28 J/cm2, 5% spot density, 1 pass for the whole scar. The treatment was done in every 2 weeks for 4 sessions
Study: NCT02704078

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EBUS-TBNA
Description: EBUS-TBNA - Patients in the Active comparator arm shall undergo mediastinal lymph node aspiration transtracheally using the EBUS scope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS-B-FNA
Description: EUS-B-FNA - Patients in the experimental arm EUS-B-FNA shall undergo mediastinal lymph node aspiration transesophageally using the EBUS scope
Study: NCT02363725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchimax®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional treatment

Intervention type: DRUG
Group type: OTHER
Intervention: Conventional treatment
Study: NCT02803307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC599
Description: Single dose via intra-articular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC599
Description: Single dose via intra-articular injection
Study: NCT00819338

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Efamax
Description: 5g daily as capsules for 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Efamax
Description: 5g daily as capsules for 3 months